These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 28150181)

  • 1. Empirical models for fitting of oral concentration time curves with and without an intravenous reference.
    Weiss M
    J Pharmacokinet Pharmacodyn; 2017 Jun; 44(3):193-201. PubMed ID: 28150181
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Generalizations in linear pharmacokinetics using properties of certain classes of residence time distributions. II. Log-concave concentration-time curves following oral administration.
    Weiss M
    J Pharmacokinet Biopharm; 1987 Feb; 15(1):57-74. PubMed ID: 3625480
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The use of a sum of inverse Gaussian functions to describe the absorption profile of drugs exhibiting complex absorption.
    Csajka C; Drover D; Verotta D
    Pharm Res; 2005 Aug; 22(8):1227-35. PubMed ID: 16078132
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of gamma distributed residence times in pharmacokinetics.
    Weiss M
    Eur J Clin Pharmacol; 1983; 25(5):695-702. PubMed ID: 6662168
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A model with separate hepato-portal compartment ("first-pass" model): fitting to plasma concentration-time profiles in humans.
    Piotrovskij V; Van Peer A
    Pharm Res; 1997 Feb; 14(2):230-7. PubMed ID: 9090715
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interpretation of plasma concentration-time curves after oral dosing.
    Ronfeld RA; Benet LZ
    J Pharm Sci; 1977 Feb; 66(2):178-80. PubMed ID: 839412
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic stochastic model with Weibull-distributed residence times of drug molecules in the body.
    Piotrovskii VK
    Eur J Clin Pharmacol; 1987; 32(5):515-23. PubMed ID: 2441996
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of plasma enfuvirtide after subcutaneous administration to patients with human immunodeficiency virus: Inverse Gaussian density absorption and 2-compartment disposition.
    Zhang X; Nieforth K; Lang JM; Rouzier-Panis R; Reynes J; Dorr A; Kolis S; Stiles MR; Kinchelow T; Patel IH
    Clin Pharmacol Ther; 2002 Jul; 72(1):10-9. PubMed ID: 12152000
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is the One-Compartment Model with First Order Absorption a Useful Approximation?
    Weiss M
    Pharm Res; 2023 Sep; 40(9):2147-2153. PubMed ID: 37594592
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetic strategies in deciphering atypical drug absorption profiles.
    Zhou H
    J Clin Pharmacol; 2003 Mar; 43(3):211-27. PubMed ID: 12638389
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Estimation of absorption ratios and their variation for orally administered drugs.
    Betzien G; Kaufmann B; Schneider B
    Eur J Clin Pharmacol; 1982; 22(3):265-72. PubMed ID: 7106160
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A note on population analysis of dissolution-absorption models using the inverse Gaussian function.
    Wang J; Weiss M; D'Argenio DZ
    J Clin Pharmacol; 2008 Jun; 48(6):719-25. PubMed ID: 18359921
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel extravascular input function for the assessment of drug absorption in bioavailability studies.
    Weiss M
    Pharm Res; 1996 Oct; 13(10):1547-53. PubMed ID: 8899849
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pitfalls and valid approaches to pharmacokinetic analysis of mean concentration data following intravenous administration.
    Cocchetto DM; Wargin WA; Crow JW
    J Pharmacokinet Biopharm; 1980 Dec; 8(6):539-52. PubMed ID: 7229907
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PHRMA CPCDC initiative on predictive models of human pharmacokinetics, part 5: prediction of plasma concentration-time profiles in human by using the physiologically-based pharmacokinetic modeling approach.
    Poulin P; Jones RD; Jones HM; Gibson CR; Rowland M; Chien JY; Ring BJ; Adkison KK; Ku MS; He H; Vuppugalla R; Marathe P; Fischer V; Dutta S; Sinha VK; Björnsson T; Lavé T; Yates JW
    J Pharm Sci; 2011 Oct; 100(10):4127-57. PubMed ID: 21541937
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of metabolite formation pharmacokinetics after intravenous and oral administration of the parent drug using inverse Laplace transformation.
    Weiss M
    Drug Metab Dispos; 1998 Jun; 26(6):562-5. PubMed ID: 9616192
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mathematical modeling of drug release profiles for modified hydrophobic HPMC based gels.
    Ghosal K; Chandra A; Rajabalaya R; Chakraborty S; Nanda A
    Pharmazie; 2012 Feb; 67(2):147-55. PubMed ID: 22512085
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PBPK models for the prediction of in vivo performance of oral dosage forms.
    Kostewicz ES; Aarons L; Bergstrand M; Bolger MB; Galetin A; Hatley O; Jamei M; Lloyd R; Pepin X; Rostami-Hodjegan A; Sjögren E; Tannergren C; Turner DB; Wagner C; Weitschies W; Dressman J
    Eur J Pharm Sci; 2014 Jun; 57():300-21. PubMed ID: 24060672
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A note on the rôle of generalized inverse Gaussian distributions of circulatory transit times in pharmacokinetics.
    Weiss M
    J Math Biol; 1984; 20(1):95-102. PubMed ID: 6491545
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A modified two-portion absorption model to describe double-peak absorption profiles of ranitidine.
    Yin OQ; Tomlinson B; Chow AH; Chow MS
    Clin Pharmacokinet; 2003; 42(2):179-92. PubMed ID: 12537516
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.